Compare PMEC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMEC | PLUR |
|---|---|---|
| Founded | 1984 | 2001 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 18.5M |
| IPO Year | 2021 | 2001 |
| Metric | PMEC | PLUR |
|---|---|---|
| Price | $0.63 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 84.1K | 24.5K |
| Earning Date | 07-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,016,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.31 | $1.06 |
| 52 Week High | $2.44 | $4.87 |
| Indicator | PMEC | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 32.26 |
| Support Level | $0.51 | N/A |
| Resistance Level | $0.80 | $1.85 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 68.75 | 10.80 |
Primech Holdings Ltd is a cleaning business. The Company operates in two segments: commercial cleaning services and robotics. The Company is an established technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The Company generates revenue from services, which include services for general cleaning and maintenance of public and private facilities; cleaning of kitchen facilities of healthcare facilities, hotels and restaurants; and the supply of ad hoc customer; and cleaning services to offices.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.